Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Multicenter study consisting of two study periods as follows: a 90-day Treatment Period, with
potential extension by 30 days for those patients requiring a dose increase, as determined by
the treating physician. Participants receiving 122.5mg of NATESTO (5.5 mg of testosterone)
per nostril twice daily may have an increased daily dose adjustment on Day 90, based on their
hypogonadism symptoms.